Novavax serum also shows high efficacy against British coronavirus mutant B.1.1.7, less so against South African mutant. US pharmaceutical company Novavax has announced a high efficacy rate for its Corona vaccine candidate. The drug showed 89.3 percent efficacy in the third and final study phase in subjects in the United Kingdom, the company announced Thursday. The vaccine could play an “important role” in managing the pandemic, Novavax CEO Stanley Erck said. The Novavax drug also showed high efficacy against the coronavirus mutant known as B.1.1.7. first identified in the United…
Read MoreNovavax: New vaccine with good efficacy
